(Q37432638)

20 August 2017

1 reference

title

Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review (English)

1 reference

20 August 2017

1 reference

1 reference

Cornelis G Gerestein

1

1 reference

20 August 2017

Ronald A M Damhuis

series ordinal

2

1 reference

20 August 2017

Curt W Burger

series ordinal

3

1 reference

20 August 2017

Geertruida S Kooi

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

2 April 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

114

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

523-527

1 reference

Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

PIEPOC: a new prognostic index for advanced epithelial ovarian cancer--Japan Multinational Trial Organization OC01-01.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Surgical care of elderly women with ovarian cancer: a population-based perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Elderly patients with stage III or IV ovarian cancer: should they receive standard care?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Neoadjuvant chemotherapy for advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Classifying cause of death after cancer surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Morbidity of cytoreductive surgery in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Management of ovarian cancer in patients older than 80 years of Age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Treatment of advanced ovarian carcinoma in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Outcomes in surgery for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Parenteral nutrition in adult inpatients with functioning gastrointestinal tracts: assessment of outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

The Department of Veterans Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

The NSQIP: a new frontier in surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Organisation and quality of primary surgical intervention for ovarian cancer in Denmark.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

The impact of subspecialty training on the management of advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Effect of surgical debulking on survival in stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Radical cytoreductive surgery combined with platinums-carboplatin and cisplatin chemotherapy for advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Factors associated with cytoreducibility among women with ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

The role of bowel surgery with cytoreduction for epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Splenectomy during primary maximal cytoreductive surgery for epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2009.03.011

1 reference

20 August 2017

1 reference